Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour

Abstract

PRRT with ¹⁷⁷Lu-octreotate can be considered a useful therapy for symptomatic somatostatin receptor-positive pancreatic NET.The clinical benefits of PRRT with ¹⁷⁷Lu-octreotate can be seen in the first months while tumour reduction can be seen up to a year after treatment.PRRT with ¹⁷⁷Lu-octreotate was clinically well tolerated and did not interfere with the subsequent surgical procedure.PRRT with ¹⁷⁷Lu-octreotate can result in significant tumour reduction and may improve surgical outcomes. As such, this therapy can be considered as a neoadjuvant therapy.